Dr Magda Osipyan
Magda is a clinician at Vardanants Medical Centre and an Associate Professor at Yerevan State Medical University.
Her research interests are connected mainly with systemic lupus erythematosus, Behçet’s disease and familial Mediterranean fever. She is fond of organising conferences and training sessions and is currently working on establishing a patient educational school for rheumatology patients in Armenia.
Magda is the secretary of Armenian rheumatological association and a member of the EMEUNET Visibility & Global Affairs Sub-Committee.
| Poster 0679| Sunday, 8.11.26, 10:30 Poster Session A; Abstract 0679 Presenting author: L. Muñoz (Spain) Title: Epidemiology of adult-onset Still’s disease in northern Spain: a 24-year population-based study  This population-based study identified 26 cases of adult-onset Still’s disease (AOSD) in Cantabria, Spain, from 2000–2023. Estimated prevalence was 4.98 per 100,000 inhabitants and incidence 0.20 per 100,000 person-years. Fever and arthralgia/arthritis were present in 96%, rash in 77%, and inflammatory markers were markedly elevated. The increasing prevalence over time may reflect improved recognition and case capture through a centralized referral system. |
| Poster 1081| Monday, 9.11.26, 10:30 Poster Session B; Abstract 1081 Presenting author: E. Deniz Batu Akal (USA) Title: Loss-of-function in NLRC3 causes a human autoinflammatory disease Investigators describe a 24-year-old man with recurrent fever and multisystem symptoms from infancy, carrying a homozygous NLRC3 p.Leu90Pro variant. Functional experiments showed increased IL-1β, IL-6 and TNF-α after stimulation, heightened NF-κB activity and enhanced STING-associated interferon signaling. Wild-type, but not mutant, NLRC3 reduced inflammatory responses. The findings identify biallelic NLRC3 loss of function as a potential cause of human autoinflammatory disease and highlight a new innate-immune regulatory checkpoint. |
| Poster 1625| Monday, 9.11.26, 10:30 Miscellaneous Rheumatic & Inflammatory Diseases Poster B (1606–1643) Presenting author: N. Hershkowitz (USA) Title: Mixed NOD-like Receptor-Associated Autoinflammatory Disease This case series describes 11 adults with mixed NOD-like receptor-associated autoinflammatory disease, with variants in two or more genes including MEFV, TNFRSF1A, NLRP3, NLRP12 and NOD2. Common features included rash (100%), arthralgia (81.8%) and abdominal pain and diarrhea (72.7% each); two-thirds had raised acute-phase reactants. Many patients did not respond adequately to colchicine or hydroxychloroquine alone, while most required IL-1 inhibition and had significant clinical responses. The report emphasizes the diagnostic complexity of overlapping, oligogenic autoinflammatory phenotypes. |
| Oral 1880| Monday, 9.11.26, 13:00 Abstract Session: Miscellaneous Rheumatic & Inflammatory Diseases: Focus on Inflammatory and Fibro-Inflammatory Disease (1880–1885) Presenting author: H. Asad (USA) Title: Cardiac Manifestations in VEXAS Syndrome In a retrospective Mayo Clinic cohort of 130 patients with VEXAS syndrome (median age 70.5 years; 99.2% male), cardiac complications were frequent. During a median two-year follow-up, 23.1% developed conduction abnormalities and 32 patients experienced arrhythmias, most commonly atrial fibrillation or nonsustained ventricular tachycardia. New heart failure occurred in 14.6%, and overall mortality was 34.6%. The findings support careful cardiovascular assessment in VEXAS, while the observational design cannot establish causality. |
| Oral 1881 | Monday, 9.11.26, 13:15 Miscellaneous Rheumatic & Inflammatory Diseases: Focus on Inflammatory and Fibro-Inflammatory Disease (1880–1885) Presenting author: S Ugurlu (Türkiye) Title: Efficacy and safety of goflikicept, an IL-1β and IL-1α inhibitor, in familial Mediterranean fever: an international randomized clinical trial In this phase 2 randomized, double-blind trial, 33 adults with colchicine-resistant or colchicine-intolerant familial Mediterranean fever and active attacks received goflikicept or placebo. Complete treatment response occurred in 68.8% (11/16) of goflikicept-treated participants versus 11.8% (2/17) receiving placebo (p=0.001). Most adverse events were mild to moderate, and the safety profile was consistent with other IL-1 inhibitors. These results suggest IL-1α/IL-1β blockade may be a promising option for patients whose FMF is inadequately controlled by colchicine; larger studies are needed. |